Nabriva Therapeutics (NBRV) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Nabriva Therapeutics plc (NBRVF)October 19, 2024 | finance.yahoo.comNabriva Therapeutics PLC NBRVFApril 13, 2024 | morningstar.comMArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesJuly 11, 2023 | finanznachrichten.deNBRV - Nabriva Therapeutics plcMay 26, 2023 | finance.yahoo.comNabriva Therapeutics (Nasdaq:NBRV) HeadlineTrading was temporarily halted for "NBRV" at 09:03 AM with a stated reason of "LULD pause."...March 27, 2023 | marketbeat.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 28, 2023 | marketwatch.comNBRV Nabriva Therapeutics plcFebruary 25, 2023 | seekingalpha.comNabriva Therapeutics Provides Corporate UpdateJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | marketwatch.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | markets.businessinsider.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | bizjournals.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | seekingalpha.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | finance.yahoo.comMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | finance.yahoo.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | technews.tmcnet.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022November 7, 2022 | finance.yahoo.comNabriva Therapeutics plc (NASDAQ:NBRV) Sees Significant Drop in Short InterestSeptember 18, 2022 | marketbeat.comNabriva Therapeutics (NASDAQ:NBRV) Reaches New 12-Month High on Analyst UpgradeSeptember 16, 2022 | marketbeat.comNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitSeptember 15, 2022 | finance.yahoo.comAll You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to BuySeptember 14, 2022 | finance.yahoo.comNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | finance.yahoo.comNabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Up 24.1% in JulyAugust 14, 2022 | marketbeat.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic FibrosisAugust 12, 2022 | marketwatch.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisAugust 11, 2022 | finance.yahoo.comNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call TranscriptAugust 3, 2022 | seekingalpha.comNabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateAugust 3, 2022 | finance.yahoo.comNabriva Therapeutics (NBRV) to Release Quarterly Earnings on WednesdayJuly 27, 2022 | marketbeat.comNabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022July 20, 2022 | finance.yahoo.comNabriva Inks Exclusive Distribution Agreement With Er-KimJuly 18, 2022 | markets.businessinsider.comNabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsJuly 18, 2022 | finance.yahoo.comNabriva Therapeutics plc (NASDAQ:NBRV) Sees Large Decline in Short InterestMay 31, 2022 | marketbeat.com$9.47 Million in Sales Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This QuarterMay 25, 2022 | marketbeat.comNabriva Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | finance.yahoo.comNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call TranscriptMay 8, 2022 | seekingalpha.comNabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateMay 5, 2022 | finance.yahoo.comNabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in USMay 5, 2022 | seekingalpha.comNabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026May 5, 2022 | finance.yahoo.comA Preview Of Nabriva Therapeutics's EarningsMay 4, 2022 | benzinga.comNabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022May 2, 2022 | finance.yahoo.comNabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisApril 11, 2022 | finance.yahoo.comNorthland Securities slashes Nabriva Therapeutics' price targetMarch 30, 2022 | seekingalpha.comNabriva Therapeutics (NASDAQ:NBRV) Price Target Cut to $2.00March 30, 2022 | marketbeat.comNabriva Therapeutics plc 2021 Q4 - Results - Earnings Call PresentationMarch 29, 2022 | seekingalpha.comNabriva Therapeutics Earnings, Revenue Miss in Q1March 29, 2022 | investing.comNabriva 4Q results indicate slowdown in topline growthMarch 29, 2022 | seekingalpha.comNabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateMarch 29, 2022 | finance.yahoo.com Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address NBRV Media Mentions By Week NBRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBRV News Sentiment▼0.000.71▲Average Medical News Sentiment NBRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBRV Articles This Week▼00▲NBRV Articles Average Week Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYBN News LYEL News TIL News CRDF News LFVN News RAPT News DERM News ACRS News SLS News PBYI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBRV) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access